FDA approves ThromboGenics vitreomacular adhesion therapy
The approval was based on the Phase III trial data which demonstrated that Jetrea is superior to placebo for the treatment of symptomatic VMA. The study reported transient,
AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.